Trump takes aim at ‘wasteful’ government spending by ordering end to penny production

Trump takes aim at ‘wasteful’ government spending by ordering end to penny production


U.S. President Donald Trump meets with Japan’s Prime Minister Shigeru Ishiba (not pictured) at the White House in Washington, U.S., Feb. 7, 2025. 
Kent Nishimura | Reuters

President Donald Trump ordered a halt to the production of new pennies, which he said will help reduce “wasteful” government spending.

“For far too long the United States has minted pennies which literally cost us more than 2 cents,” Trump said in a Truth Social post. “This is so wasteful! I have instructed my Secretary of the US Treasury to stop producing new pennies. Let’s rip the waste out of our great nations budget, even if it’s a penny at a time,” Trump wrote.

It’s not clear whether the president has the authority to stop the manufacture of the currency. According to the U.S. Constitution, coinage power, as recognized by the Supreme Court, is “exclusive” to Congress. Federal law says the Treasury secretary can mint and issue coins as necessary for the needs of the United States.

But at least one analyst on Wall Street expects that the penny’s days are numbered. TD Cowen’s Jaret Seiberg said the halt will likely pass judicial review, leading to a shortage of the coin.

“We believe this order would survive judicial review, which is why this is likely to occur,” Seiberg wrote Monday. “We worry about this leading to a shortage of pennies, which could force merchants to pay banks more for coins. It also adds legal risk for merchants and banks. That could create the crisis needed to force Congress to act.”

Seiberg said he expects this could support the move toward electronic payments, bolstering companies such as Visa, Mastercard and other real-time payment networks.

What is clear is that pennies cost to make than they are worth. In 2024, the U.S. Mint spent 3.69 cents to manufacture each penny, according to an annual report. That meant the cost of each penny has run above its face value for a 19th straight fiscal year.

The latest U.S. Mint report suggests the nickel better watch its back, too. Each 5-cent piece costs the Mint 13.78 cents to make.

Don’t miss these insights from CNBC PRO

  • Goldman tells clients these stocks are most at risk from Trump’s tariffs
  • Here are the stocks that will be hurt the most from Trump’s new tariffs
  • Tom Lee says buy this tariff dip in stocks, but bitcoin is headed for much more short-term pain
  • IBM is the best Dow stock over the past 3 months, but one CIO says its AI message is disappointing



Source

Kevin Hassett pivots to possible ‘Trump cards’ amid credit card battle with banks
Finance

Kevin Hassett pivots to possible ‘Trump cards’ amid credit card battle with banks

Key Points Kevin Hassett told Fox Business that U.S. banks could voluntarily provide credit cards to underserved Americans. President Donald Trump called for banks to cap credit card interest rates at 10%, an idea that has been roundly rejected by industry executives and their lobbyists this week. At least one major credit card issuer and […]

Read More
Stocks making the biggest moves midday: Novo Nordisk, Vistra, GE Vernova, Regions Financial and more
Finance

Stocks making the biggest moves midday: Novo Nordisk, Vistra, GE Vernova, Regions Financial and more

Check out some of the companies making headlines in midday trading: Novo Nordisk — The maker of the Wegovy obesity treatment jumped more than 4% as sales of its oral weight loss treatment got off to a strong start. In the first week of its launch, about 1.3% of Wegovy prescriptions were for the oral […]

Read More
Stocks making the biggest moves premarket: PNC, ImmunityBio, Coupang & more
Finance

Stocks making the biggest moves premarket: PNC, ImmunityBio, Coupang & more

Check out the companies making headlines before the bell. ImmunityBio — The biotech company rallied 22%, adding to a 30% rally in the previous session that was sparked by strong guidance for its bladder cancer drug Anktiva. ImmunityBio expects full-year revenue for the drug to jump 700%. Coupang — Shares rose more than 3% after […]

Read More